Please login to the form below

Not currently logged in
Email:
Password:

Hospira

This page shows the latest Hospira news and features for those working in and with pharma, biotech and healthcare.

J&J and Pfizer quietly resolve Remicade biosimilar lawsuit

J&J and Pfizer quietly resolve Remicade biosimilar lawsuit

Inflectra was originally developed by South Korea-based Celltrion and licensed in 2009 by Hospira, which Pfizer then acquired for $15bn in 2015.

Latest news

More from news
Approximately 12 fully matching, plus 67 partially matching documents found.

Latest Intelligence

  • Innovation in merger control and the impact on the pharmaceutical sector Innovation in merger control and the impact on the pharmaceutical sector

    For example, in the Pfizer/Hospira merger, the Commission found that the proposed transaction raised competition concerns because Pfizer was developing a competing medicine to Hospira’s. ... Specifically, Hospira was selling Inflectra, an infliximab

  • Deal Watch October 2016 Deal Watch October 2016

    These two biosimilars were originally licensed by Hospira but when Pfizer acquired Hospira it terminated the agreement. ... For example in Europe both Pfizer (Hospira) in 2009 and Mundipharma in 2014 have rights to Celltrion's infliximab.

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    This first infliximab biosimilar was developed and manufactured by Celltrion and is marketed by various partners, notably Hospira under the brand name Inflectra and Mundipharma as Remsima.

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    The top major pharma mergers, acquisitions and collaborations during the month were led by the Pfizer/Hospira and Salix/Valeant deals. ... Majority acquisition. 380. Pfenex/ Hospira. PF582 - LUCENTIS biosimilar candidate - wet age-related macular

  • Pharma deals in February 2015 Pharma deals in February 2015

    There are no approved biosimilars in the US where Hospira awaits approval of Remicade and Retacrit. ... No doubt Pfizer had hoped Hospira's persistent manufacturing problems were a thing of the past.

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
foxandcat.online

We help communications teams to thrive under pressure. Here at fox&cat, we help all kinds of teams to fight all...

Latest intelligence

The communication challenge of helping he next generation to be healthier
As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
Are we losing sight of what the democratisation of healthcare really looks like?
We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation
...